Interestingly, 3 intronic polymorphisms of functional relevance on the basis of in-silico studies, with a potential of generating splice variants and aberrant PKM2 protein, could be evaluated as cancer markers, and their prevalence in cancer patients and general population assessed for the proposed metabolic relevance. This evidence concerns the gene PKM and cancer.